S&P 500
7,582.20
+0.03%
Dow Jones
51,018.80
+0.58%
Nasdaq 100
30,344.40
+0.25%
Russell 2000
2,916.31
-0.54%
FTSE 100
10,378.60
-0.32%
Nikkei 225
66,231.90
+0.67%

Health and Healthcare

Achillion Pharmaceuticals Gears Up for Secondary Offering

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Achillion Pharmaceuticals Gears Up for Secondary Offering

© Thinkstock

Shares of Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) saw a handy gain on Thursday after the company announced a secondary offering. While the offering is set to close on November 20, the company will not receive any proceeds. Instead, the selling shareholders will.

The 18.367 million shares in the offering are being sold by Johnson & Johnson (NYSE: JNJ) at $2.75 apiece. The entire offering is valued up to $50.51 million.

The underwriters for the offering are Goldman Sachs and Leerink Partners.

Achillion is a science-driven, patient-focused biopharmaceutical company seeking to leverage its strengths across the continuum from discovery through commercialization by discovering and developing small molecule therapeutics to meet the needs of patients with complement-mediated diseases.

[nativounit]

Its current focus is on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is a part of the human innate immune system and is believed to comprise three pathways: the alternative pathway, the lectin pathway and the classical pathway.

Recently, the company said:

On November 14, 2017, we reported preliminary proof-of-concept results from the first patient group in our on-going phase II, open-label, 14-day study of ACH-4471 for patients with C3G or IC-MPGN. Interim data from the first patient group, consisting of two sentinel patients, demonstrated that ACH-4471 achieved complement alternative pathway inhibition resulting in a greater than 50% reduction in proteinuria, as measured by albumin to creatinine ratio over the 14-day treatment period, and demonstrated a favorable tolerability profile.

Keep in mind that the stock is down about 26% year to date, excluding Thursday’s move.

Shares of Achillion were last seen up about 10% at $3.35, with a consensus analyst price target of $5.92 and a 52-week trading range of $2.95 to $5.66.

Johnson & Johnson traded at $139.23. The stock has a 52-week range of $109.32 to $144.35 and a consensus price target of $145.33.

[wallst_email_signup]

DISCLOSURE:
INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org). Advisory services are offered by SoFi Wealth LLC, an SEC-registered investment adviser. Information about SoFi Wealth’s advisory operations, services, and fees is set forth in SoFi Wealth’s current Form ADV Part 2 (Brochure), a copy of which is available upon request and at www.adviserinfo.sec.gov. Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 30 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees. Investing in alternative investments and/or strategies may not be suitable for all investors and involves unique risks, including the risk of loss. An investor should consider their individual circumstances and any investment information, such as a prospectus, prior to investing. Interval Funds are illiquid instruments, the ability to trade on your timeline may be restricted. Brokerage and Active investing products offered through SoFi Securities LLC, Member FINRA(www.finra.org) /SIPC(www.sipc.org). There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event. Options involve risks, including substantial risk of loss and the possibility an investor may lose the entire investment Before trading options please review the Characteristics and Risks of Standardized Options  Investing in an Initial Public Offering (IPO) involves substantial risk, including the risk of loss. Further, there are a variety of risk factors to consider when investing in an IPO, including but not limited to, unproven management, significant debt, and lack of operating history. For a comprehensive discussion of these risks please refer to SoFi Securities’ IPO Risk Disclosure Statement This should not be considered a recommendation to participate in IPOs and investors should carefully read the offering prospectus to determine whether an offering is consistent with their investment objectives, risk tolerance, and financial situation. New offerings generally have high demand and there are a limited number of shares available for distribution to participants. Many customers may not be allocated shares and share allocations may be significantly smaller than the shares requested in the customer’s initial offer (Indication of Interest). For more information on the allocation process please visit IPO Allocation.
Follow 24/7 Wall St. on Google
Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Achillion Pharma Slides After Hep C Deal Is Terminated
Chris Lange |

Achillion Pharma Slides After Hep C Deal Is Terminated

Achillion Pharmaceuticals saw its shares slump early on Monday after the firm announced that its hepatitis C license and collaboration…

Akari Therapeutics Soars on Positive Preliminary Results
Chris Lange |

Akari Therapeutics Soars on Positive Preliminary Results

Akari Therapeutics has announced preliminary results from the first paroxysmal nocturnal hemoglobinuria patient treated with subcutaneously administered Coversin.

Lee Jackson |

4 Biotechs Expected to See Huge Buying on PowerShares Rebalance

All the major money management firms that run exchange traded funds have to do regular quarterly rebalances to reset their…

Goldman Sachs Has 4 Red-Hot Biotech Stocks to Buy Under $10
Lee Jackson |

Goldman Sachs Has 4 Red-Hot Biotech Stocks to Buy Under $10

These four sizzling biotech stocks trading under the $10 level have big upside to the analysts' price targets. All of…

4 Biotech and Life Sciences Stocks Trading Under $10 With Gigantic Upside Potential
Lee Jackson |

4 Biotech and Life Sciences Stocks Trading Under $10 With Gigantic Upside Potential

These are four stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential.…

Goldman Sachs Has 4 Sizzling Biotech Stocks to Buy That Are Under $10
Lee Jackson |

Goldman Sachs Has 4 Sizzling Biotech Stocks to Buy That Are Under $10

These four sizzling biotech stocks trading under the $10 level could provide investors with some solid upside potential. They are…

Chris Lange |

Omeros Shares Doubling on Positive Phase 2 Data

ThinkstockOmeros Corp. (NASDAQ: OMER) is flying high in Tuesday’s trading session with shares practically doubling on positive phase 2 news.…

Chris Lange |

What Lit a Fire Under These 3 Pharma Stocks

Over the past week, a few pharmaceutical companies made absolutely massive runs.

Baird Has 3 Top Biotech Picks With Huge Upcoming Potential Catalysts
Lee Jackson |

Baird Has 3 Top Biotech Picks With Huge Upcoming Potential Catalysts

These three biotech stocks have upcoming clinical data and presentations that could be huge, and they could blast the stocks…

Top Gaining Stocks

Dell Technologies
DELL • Vol: 42,366,555
NetApp
NTAP • Vol: 15,911,807
ServiceNow
NOW • Vol: 68,243,561
IBM
IBM • Vol: 28,527,546
Hewlett Packard Enterprise
HPE • Vol: 86,996,387

Top Losing Stocks

Coterra Energy
CTRA • Vol: 73,319,495
Clorox
CLX • Vol: 4,744,001
ResMed
RMD • Vol: 3,526,686
Intel
INTC • Vol: 191,680,425
Skyworks Solutions
SWKS • Vol: 5,407,806